title: [Curative efficiency of rituximab combined with autologous cytokine induced killer cells on aged patient with orbital diffuse large B cell lymphoma].
abstract: The aim of this study was to observe the curative effects and safety of autologous cytokine induced killer (CIK) cells in treatment of aged patients with orbital diffuse large B cell lymphoma after rituximab therapy. The patient was given rituximab three times with low dose COP chemotherapy one time when he was diagnosed with orbital diffuse large B cell lymphoma. Two months later, the patient began to receive five cycles CIK cells infusion. One course of therapy was defined as follows: about (2-3)×10(9) of CIK cells (survival rate > 95%) was transfused twice and then rhIL-2 (1 MU daily) was subcutaneously administered for 10 consecutive days. Efficacy and adverse effect was observed during or after CIK cells infusion. The results showed that the peripheral blood mononuclear cells of the patient could be cultured and expanded into CIK cells. The majority of CIK cells was positive for CD3 and CD8 after culture. The CD3(+)CD56(+) cells markedly increased after culture. After two cycles of CIK cell infusion, the orbital lymphoma and possible involvement of the kidney disappeared. The patient obtained complete remission after five cycles of CIK cells infusion. The side effects of CIK cell treatment were minor. It is concluded that CIK cell infusion may prevent recurrence, prolong progression-free survival and improve quality of life after rituximab (alone or with chemotherapy) for aged patients with orbital diffuse large B-cell lymphoma.
authors.affiliation: Department of Geriatric Hematology, PLA General Hospital, Beijng, China.
authors.forename: Su-Xia
authors.initials: SX
authors.lastname: Li
authors.forename: Hong-Li
authors.initials: HL
authors.lastname: Zhu
authors.forename: Bo
authors.initials: B
authors.lastname: Guo
authors.forename: Xue-Chun
authors.initials: XC
authors.lastname: Lu
authors.forename: Hui
authors.initials: H
authors.lastname: Fan
authors.forename: Jie
authors.initials: J
authors.lastname: Lin
authors.forename: Bo
authors.initials: B
authors.lastname: Yang
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.forename: Yang
authors.initials: Y
authors.lastname: Yang
authors.forename: Hai-Hong
authors.initials: HH
authors.lastname: Ran
authors.forename: Bing
authors.initials: B
authors.lastname: Zhai
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Han
authors.forename: Yao
authors.initials: Y
authors.lastname: Wang
authors.forename: Shan-Qian
authors.initials: SQ
authors.lastname: Yao
mesh_terms: D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D055612:Cytokine-Induced Killer Cells / Q000166:cytology / Q000637:transplantation*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D008297:Male; D009918:Orbital Neoplasms / Q000628:therapy*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab